Second-generation HIV microbicides: Continued development of Griffithsin

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 15, 2009, Pages 6029-6030

  Zeitlin, Larry ^a   Pauly, Michael ^a   Whaley, Kevin J ^a  

^a Mapp Biopharmaceutical Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARBOPOL 974P; CARRAGEENAN; CELLULOSE SULFATE; DAPIVIRINE; GRIFFITHSIN; MICROBICIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NONOXINOL 9; PRO 2000; RECOMBINANT PROTEIN; SAVVY; TENOFOVIR; UNCLASSIFIED DRUG; VIVAGEL; ALGAL PROTEIN; GRIFFITHSIN PROTEIN, GRIFFITHSIA; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; LECTIN;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG FORMULATION; DRUG MANUFACTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NOTE; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; VIRUS ENTRY; ANIMAL; DRUG DESIGN; DRUG EFFECT; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; METABOLISM; PROTEIN BINDING;

ALGAL PROTEINS; ANIMALS; DRUG DESIGN; FEMALE; HIV FUSION INHIBITORS; HIV-1; HUMANS; LECTINS; MALE; PROTEIN BINDING;

EID: 65549167306     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0902239106     Document Type: Note

References (17)

1. O'Keefe BR et al. (2009) Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc Natl Acad Sci USA 106:6099-6104.
2. Grant RM, et al. (2008) Whither or wither microbicides? Science 321:532-534.
3. Skoler-Karpoff S, et al. (2008) Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372:1977-1987.
4. Karim SA, et al. Safety and effectiveness of vaginal microbicides BufferGel and 0.5% PRO 2000/5 gel for the prevention of HIV infection in women: Results of the HPTN 035 Trial. 16th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2009, Montreal, Canada, abstr 48LB. Available at www. retroconference.org/2009/Abstracts/36659.htm.
5. Lard-Whiteford SL, et al.; International Working Group on Microbicides (2004) Recommendations for the nonclinical development of topical microbicides for prevention of HIV transmission: an update. J Acquir Immune Defic Syndr 36:541-552.
6. Mori T, et al. (2005) Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem 280:9345-9353.
7. Emau P et al. (2007) Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV micro-bicide. J Med Primatol 36: 244-253.
8. Lackman-Smith C, et al. (2008) Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrob Agents Che-mother 52:1768-1781.
9. McCormick AA, et al. (2008) Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lym-phoma: Safety and immunogenicity in a phase I clinical study. Proc Natl Acad Sci USA 105:10131-10136.
10. McCormick AA, et al. (2003) Individualized human scfv vaccines produced in plants: Humoral anti-idiotype responses in vaccinated mice confirm relevance to the tumor ig. J Immunol Methods 278:95-104.
11. Gleba Y, Klimyuk V, Marillonnet S (2005) Magnifec-tion - A new platform for expressing recombinant vaccines in plants. Vaccine 23:2042-2048.
12. Hiatt A, Pauly M (2006) Monoclonal antibodies from plants: A new speed record. Proc Natl Acad Sci USA 103:14645-14646.
13. Schä hs M, et al. (2007) Production of a monoclonal antibody in plants with a humanized N-glycosylation pattern. Plant Biotechnol J 5:657-663.
14. Glasier A, Gü lmezoglu A, Schmid G, Moreno C, Van Look P (2006) Sexual and reproductive health: A matter of life and death. Lancet 368:1595-1607.
15. Chesson HW, Pinkerton SD (2000) Sexually transmitted diseases and the increased risk for HIV transmission: Implications for cost-effectiveness analyses of sexually transmitted disease prevention interventions. J Acquir Immune Defic Syndr 24:48-56.
16. Nusbaum MR, Wallace RR, Slatt LM, Kondrad EC (2004) Sexually transmitted infections and increased risk of co-infection with human immunodeficiency virus. J Am Osteopath Assoc 104:527-535.
17. Moench TR, Chipato T, Padian NS (2001) Preventing disease by protecting the cervix: the unexplored promise of internal vaginal barrier devices. AIDS 15:1595-1602.